Strategy
Turning Science into Consumer Brands
Our strategy is to acquire, through purchase or licence, products with proven innovative and relevant claims that have yet to be developed to their commercial potential. These could be, for example:
- Products with successful clinical trials and ideally registrations, that have yet to be introduced into the OTC market.
- Brands that have been successfully launched in one market but whose owners lack the resources and/or experience to develop them internationally.
- Products or brands which, in spite of having a differentiated claim within a specific category, fall outside the corporate strategic agenda of their current owners.
Markets
HBI is operating in most markets around the world with a particular focus on Europe. By using a virtual organisation we are able to develop an entry plan for a specific country by finding the appropriate local expertise whether it be manufacturing, sales or regulatory.
Sambucol, our first brand, is a black elderberry extract which helps support the immune system. Sambucol is the only black elderberry extract to be clinically tested. Sambucol has now been sold to PharmaCare of Australia
Erazaban is a new HBI brand and contains Docosanol, an active which is the cold-sore market leader in the US. Erazaban gives HBI the unique opportunity to market this new, patented active ingredient across Europe. Having obtained a pan European OTC approval and launched the product in several markets, Erazaban rights in various markets have been sold to local partners.